Keating Financial Advisory Services »

Keros Therapeutics shares owned by Keating Financial Advisory Services

Quarter-by-quarter ownership of Keros Therapeutics (KROS) shares owned by Keating Financial Advisory Services from 13F filings

Historical chart of Keating Financial Advisory Services investment in Keros Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Keros Therapeutics held by Keating Financial Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Keros Therapeutics by Keating Financial Advisory Services

Quarter filed Position value Share count Share price at filing
2026-03-31 $55 5 11.00

More positions owned by Keating Financial Advisory Services

Apple (AAPL)
Dimensional Us Core Equity Market Etf Us Core Eqt Mkt (DFAU)
NVIDIA Corporation (NVDA)
Vanguard Index Funds S&p 500 Etf S&p 500 Etf Shs (VOO)
Dimensional Us High Profitability Etf Us High Profitab (DUHP)
State Street Spdr S&p 500 Etf Trust Tr Unit (SPY)
Dimensional International Core Equity Market Etf Intl Core Eqt Mk (DFAI)
Microsoft Corporation (MSFT)
Dimensional Core Fixed Income Etf Core Fixed Incom (DFCF)
Invesco S&p 500 Momentum Etf S&p 500 Momntm (SPMO)
Schwab U.s. Large-cap Growth Etf Us Lcap Gr Etf (SCHG)
Invesco Qqq Trust Unit Ser 1 (QQQ)
Amazon (AMZN)
Dimensional International High Profitability Etf Intl High Profit (DIHP)
Dimensional Us Core Equity 1 Etf Us Core Equity 1 (DCOR)

View all positions for Keating Financial Advisory Services

Top funds holding Keros Therapeutics

BlackRock
Vanguard Group
Nantahala Capital Management
Arrowstreet Capital, Limited Partnership
State Street Corporation
Vanguard Capital Management
Madison Avenue Partners
Qube Research & Technologies
OrbiMed Advisors
Jacobs Levy Equity Management
Federated Investors
Vanguard Portfolio Management
Geode Capital Management
Renaissance Technologies
Citadel Advisors

View all funds holding Keros Therapeutics